N-acetyl-aspartate (NAA) as a correlate of pharmacological treatment in psychiatric disorders: A systematic review

European Neuropsychopharmacology

Volumn 24, Issue 10, 2014, Pages 1659-1675

  Paslakis, Georgios ^a   Träber, Frank ^a   Roberz, Jens ^a   Block, Wolfgang ^a   Jessen, Frank ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Affective disorder; Alzheimer dementia; N acetyl aspartate; Obsessive compulsive disorder; Proton MR spectroscopy; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DONEPEZIL; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GALANTAMINE; HALOPERIDOL; ICOSAPENTAENOIC ACID; LITHIUM; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID; VENLAFAXINE; ASPARTIC ACID; N-ACETYLASPARTATE;

ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; BRAIN LEVEL; CELL METABOLISM; CORRELATION ANALYSIS; DEMENTIA; DEPRESSION; DRUG EFFECT; DRUG RESPONSE; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MITOCHONDRION; MOOD DISORDER; NERVE CELL; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; BRAIN; DRUG EFFECTS; MENTAL DISORDERS; METABOLISM;

ASPARTIC ACID; BRAIN; HUMANS; MENTAL DISORDERS; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84908053444     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.06.004     Document Type: Article

References (50)

1. Anglin R.E., Mazurek M.F., Tarnopolsky M.A., Rosebush P.I. The mitochondrial genome and psychiatric illness. Am. J. Med. Genet. Part B, Neuropsychiatr. Genet. 2012, 159B:749-759.
2. Arun P., Moffett J.R., Namboodiri A.M. Evidence for mitochondrial and cytoplasmic N-acetylaspartate synthesis in SH-SY5Y neuroblastoma cells. Neurochem. Int. 2009, 55:219-225.
3. Bartha R., Smith M., Rupsingh R., Rylett J., Wells J.L., Borrie M.J. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:786-793.
4. Baslow M.H. Evidence that the tri-cellular metabolism of N-acetylaspartate functions as the brain[U+05F3]s "operating system": how NAA metabolism supports meaningful intercellular frequency-encoded communications. Amino Acids 2010, 39:1139-1145.
5. Baslow M.H. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem. Res. 2003, 28:941-953.
6. Bates T.E., Strangward M., Keelan J., Davey G.P., Munro P.M., Clark J.B. Inhibition of N-acetylaspartate production: implications for 1H-MRS studies in vivo. Neuroreport 1996, 7:1397-1400.
7. Bertolino A., Callicott J.H., Mattay V.S., Weidenhammer K.M., Rakow R., Egan M.F., Weinberger D.R. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry 2001, 49:39-46.
8. Block W., Träber F., von Widdern O., Metten M., Schild H., Maier W., Zobel A., Jessen F. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int. J. Neuropsychopharmacol. 2009, 12:415-422.
9. Brown T.R. Practical applications of chemical shift imaging. NMR Biomed. 1992, 5:238-243.
10. Bustillo J.R., Lauriello J., Rowland L.M., Thomson L.M., Petropoulos H., Hammond R., Hart B., Brooks W.M. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr. Res. 2002, 58:313-321.
11. Bustillo J.R., Rowland L.M., Jung R., Brooks W.M., Qualls C., Hammond R., Hart B., Lauriello J. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 2008, 33:2456-2466.
12. Bustillo J.R., Rowland L.M., Mullins P., Jung R., Chen H., Qualls C., Hammond R., Brooks W.M., Lauriello J. 1H-MRS at 4 T in minimally treated early schizophrenia. Mol. Psychiatry 2010, 15:629-636.
13. Cheng L.L., Ma M.J., Becerra L., Ptak T., Tracey I., Lackner A., González R.G. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:6408-6413.
14. Clark J.B. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev. Neurosci. 1998, 20:271-276.
15. Dautry C., Vaufrey F., Brouillet E., Bizat N., Henry P.G., Condé F., Bloch G., Hantraye P. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 2000, 20:789-799.
16. DelBello M.P., Cecil K.M., Adler C.M., Daniels J.P., Strakowski S.M. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2006, 31:1264-1273.
17. Fannon D., Simmons A., Tennakoon L., O'Céallaigh S., Sumich A., Doku V., Shew C., Sharma T. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol. Psychiatry 2003, 54:587-598.
18. Frangou S., Lewis M., Wollard J., Simmons A. Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J. Psychopharmacol. 2007, 21:435-439.
19. Friedman S.D., Dager S.R., Parow A., Hirashima F., Demopulos C., Stoll A.L., Lyoo I.K., Dunner D.L., Renshaw P.F. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol. Psychiatry 2004, 56:340-348.
20. Gonul A.S., Kitis O., Ozan E., Akdeniz F., Eker C., Eker O.D., Vahip S. The effect of antidepressant treatment on N-acetyl aspartate levels of medial frontal cortex in drug-free depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:120-125.
21. Henigsberg N., Bajs M., Hrabac P., Kalember P., Rados M., Rados M., Radonić E. Changes in brain metabolites measured with magnetic resonance spectroscopy in antidepressant responders with comorbid major depression and posttraumatic stress disorder. Coll. Antropol. 2011, 35(Suppl. 1):145-148. (A).
22. Henigsberg N., Kalember P., Hrabać P., Rados M., Bajs M., Rados M., Kovavić Z., Loncar M., Madzar T. 1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer[U+05F3]s disease. Coll. Antropol. 2011, 35(Suppl. 1):159-162.
23. Huang Y., Chen W., Li Y., Wu X., Shi X., Geng D. Effects of antidepressant treatment on N-acetyl aspartate and choline levels in the hippocampus and thalami of post-stroke depression patients: a study using (1)H magnetic resonance spectroscopy. Psychiatry Res. 2010, 182:48-52.
24. Jang J.H., Kwon J.S., Jang D.P., Moon W.J., Lee J.M., Ha T.H., Chung E.C., Kim I.Y., Kim S.I. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder. Am. J. Psychiatry 2006, 163:1202-1207.
25. Jessen F., Traeber F., Freymann K., Maier W., Schild H.H., Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 2006, 67:528-530.
26. Kaymak S.U., Demir B., Oguz K.K., Senturk S., Ulug B. Antidepressant effect detected on proton magnetic resonance spectroscopy in drug-naive female patients with first-episode major depression. Psychiatry Clin. Neurosci. 2009, 63:350-356.
27. Krishnan K.R., Charles H.C., Doraiswamy P.M., Mintzer J., Weisler R., Yu X., Perdomo C., Ieni J.R., Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer[U+05F3]s disease. Am. J. Psychiatry 2003, 160:2003-2011.
28. Lentz M.R., Kim J.P., Westmoreland S.V., Greco J.B., Fuller R.A., Ratai E.M., He J., Sehgal P.K., Halpern E.F., Lackner A.A., Masliah E., González R.G. Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain. Radiology 2005, 235:461-468.
29. Manji H., Kato T., Di Prospero N.A., Ness S., Beal M.F., Krams M., Chen G. Impaired mitochondrial function in psychiatric disorders. Nat. Rev. Neurosci. 2012, 13:293-307.
30. Maudsley A.A., Wu Z., Meyerhoff D.J., Weiner M.W. Automated processing for proton spectroscopic imaging using water reference deconvolution. Magn. Reson. Med. 1994, 31:589-595.
31. Michael N., Erfurth A., Ohrmann P., Arolt V., Heindel W., Pfleiderer B. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 2003, 28:720-725.
32. Modrego P.J., Pina M.A., Fayed N., Diaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer[U+05F3]s disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 2006, 20:867-877.
33. Moffett J.R., Ross B., Arun P., Madhavarao C.N., Namboodiri A.M. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 2007, 81:89-131.
34. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., Faulk M.W., Koch S., Glitz D.A., Jolkovsky L., Manji H.K. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2[U+05F3]s neurotrophic effects? Biol. Psychiatry 2000, 48:1-8.
35. Pae C.U., Choe B.Y., Joo R.H., Lim H.K., Kim T.S., Yoo S.S., Choi B.G., Kim J.J., Lee S.J., Lee C., Paik I.H., Lee C.U. Neuronal dysfunction of the frontal lobe in schizophrenia. Neuropsychobiology 2004, 50:211-215.
36. Pajonk F.G., Wobrock T., Gruber O., Scherk H., Berner D., Kaizl I., Kierer A., Müller S., Oest M., Meyer T., Backens M., Schneider-Axmann T., Thornton A.E., Honer W.G., Falkai P. Hippocampal plasticity in response to exercise in schizophrenia. Arch. Gen. Psychiatry 2010, 67:133-143.
37. Pan J.W., Takahashi K. Interdependence of N-acetyl aspartate and high-energy phosphates in healthy human brain. Ann. Neurol. 2005, 57:92-97.
38. Parlayan E., Yulug B., Bakar M., Gumustas O. Neurometabolic correlations of donepezil and rivastigmine in dementia patients: a different neuroprotective effect. J. Neuropsychiatry Clin. Neurosci. 2009, 21:348-350.
39. Penner J., Rupsingh R., Smith M., Wells J.L., Borrie M.J., Bartha R. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:104-110.
40. Premkumar P., Parbhakar V.A., Fannon D., Lythgoe D., Williams S.C., Kuipers E., Kumari V. N-acetyl aspartate concentration in the anterior cingulate cortex in patients with schizophrenia: a study of clinical and neuropsychological correlates and preliminary exploration of cognitive behaviour therapy effects. Psychiatry Res. 2010, 182:251-260.
41. Rosenberg D.R., MacMaster F.P., Keshavan M.S., Fitzgerald K.D., Stewart C.M., Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J. Am. Acad. Child. Adolesc. Psychiatry 2000, 39:1096-1103.
42. Schirmer T., Auer D.P. On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain. NMR Biomed. 2000, 13:28-36.
43. Sonawalla S.B., Renshaw P.F., Moore C.M., Alpert J.E., Nierenberg A.A., Rosenbaum J.F., Fava M. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am. J. Psychiatry 1999, 156(10):1638-1640.
44. Szulc A., Galinska B., Tarasow E., Dzienis W., Kubas B., Konarzewska B., Walecki J., Alathiaki A.S., Czernikiewicz A. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H-MRS). Pharmacopsychiatry 2005, 38:214-219.
45. Szulc A., Galinska B., Tarasow E., Waszkiewicz N., Konarzewska B., Poplawska R., Bibulowicz D., Simonienko K., Walecki J. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. Pharmacopsychiatry 2011, 44:148-157.
46. Taylor M.J., Godlewska B.R., Norbury R., Selvaraj S., Cowen J. Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. Int. J. Neuropsychopharmacol. 2012, 15:1541-1546.
47. Träber F., Block W., Freymann N., Gür O., Kucinski T., Hammen T., Ende G., Pilatus U., Hampel H., Schild H.H., Heun R., Jessen F. A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe. Eur. Radiol. 2006, 16:1096-1103.
48. Urenjak J., Williams S.R., Gadian D.G., Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 1992, 59:55-61.
49. Wang Y., Jia Y., Chen X., Ling X., Liu S., Xu G., Huang L. Hippocampal N-acetylaspartate and morning cortisol levels in drug-naive, first-episode patients with major depressive disorder: effects of treatment. J. Psychopharmacol. 2012, 26:1463-1470.
50. Wood S.J., Berger G.E., Wellard R.M., Proffitt T., McConchie M., Velakoulis D., McGorry P.D., Pantelis C. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naive and early-treated first episode psychosis. Schizophr. Res. 2008, 102:163-170.